New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
12:39 EDTAVNR, BMY, ISIS, BIIB, SNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
News For BMY;SNY;ISIS;AVNR;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 29, 2015
17:23 EDTBMYBristol-Myers gets FDA approval for Evotaz to treat HIV-1 infections
Subscribe for More Information
17:07 EDTBIIBBiogen hits fresh lifetime high, levels to watch
Subscribe for More Information
16:13 EDTBIIBBiogen shares jump 5% to $371 after 2015 outlook top estimates
Subscribe for More Information
16:12 EDTBIIBBiogen reports Q4 Tecfidera revenue $916M vs. $397.6M last year
Subscribe for More Information
16:10 EDTBIIBBiogen sees 2015 EPS $16.60-$17.00, consensus $16.37
Subscribe for More Information
16:09 EDTBIIBBiogen reports Q4 EPS $4.09, consensus $3.78
Subscribe for More Information
12:00 EDTBIIBLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
08:14 EDTBMYCelldex, Bristol-Myers initiate Phase 1/2 Varlilumab, Opdivo combination study
Subscribe for More Information
05:30 EDTBIIBBiogen, Fondazione Telethon and Ospedale San Raffaele announce collaboration
Subscribe for More Information
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
07:37 EDTBMYBristol-Myers sees FY15 EPS $1.55-$1.70, consensus $1.71
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q4 EPS 46c, consensus 41c
Subscribe for More Information
January 26, 2015
15:40 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
11:29 EDTBMYBristol-Myers January weekly volatility increases into Q4 and outlook
Subscribe for More Information
05:14 EDTSNYRegeneron, Sanofi announce BLA for Praluent accepted for priority review by FDA
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the Biologics License Application, or BLA, for Praluent, alirocumab. Under the Prescription Drug User Fee Act, or PDUFA, the goal for a priority review is six months, for a target action date of July 24. Alirocumab is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.
January 22, 2015
08:49 EDTBMYBristol-Myers price target raised to $70 from $63 at SunTrust
Subscribe for More Information
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
10:16 EDTSNY, BMYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:34 EDTBMYBristol-Myers appoints Giovanni Caforio CEO
Bristol-Myers Squibb announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May. Giovanni Caforio, M.D. will become CEO of the company. Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Togo D. West, Jr., 72, will become the lead independent director on the company’s board.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use